Читать книгу Nanovaccinology as Targeted Therapeutics - Группа авторов - Страница 3

1 Chapter 2Table 2.1 A list of targeted delivery tools used against pathogens and diseases.Table 2.2 Some commercial nanomaterial products approved by FDA and EMA.

2 Chapter 3Table 3.1 Types of nanovaccines against superbugs.

3 Chapter 4Table 4.1 WHO-approved SARS-CoV2 vaccines.Table 4.2 SARS-CoV2 vaccines in Phase 4 clinical trials.

4 Chapter 8Table 8.1 Antibacterial effect of 2C6NA nanocrystals.Table 8.2 Fungal approach of 2C6NA nanocrystals.Table 8.3 Antioxidant and antidiabetic data of 2C6NA nanocrystals.Table 8.4 Details of samples received for the study.Table 8.5 Concentrations used for the study.

5 Chapter 9Table 9.1 Data of SXRD of BGLBMH crystals.Table 9.2 Milling of BGLBMH crystals for nanoscaling.Table 9.3 AD of macro, nano BGLBMH crystals.Table 9.4 Influx of macro, nano BGLBMH crystals.Table 9.5 AO of macro, nano BGLBMH crystals.

6 Chapter 10Table 10.1 Energy densities of crystals of N2MNM4MBH.Table 10.2 Antidiabetic effects of both scales.

7 Chapter 11Table 11.1 ZnO-MIZN—antibacterial activity.Table 11.2 Phase composition, structural, and microstructural parameters as obta...Table 11.3 Magnetic properties of biogenic ZnO nano powders.

8 Chapter 12Table 12.1 Interaction energies and surface info of 2F5NA.Table 12.2 Biouses of 2F5NA crystals.

9 Chapter 13Table 13.1 Antidiabetic data for macro and nano AMPHB crystals.Table 13.2 Anti-inflammatory data for macro and nano AMPHB crystals.Table 13.3 Anti-fungal activity for macro and nano AMPHB crystals.

10 Chapter 14Table 14.1 XRD of CPDMDP macro crystals.Table 14.2 Influx of macro, nano CPDMDP crystals.Table 14.3 AD of macro, nano CPDMDP crystals.Table 14.4 AO of macro, nano CPDMDP crystals.

11 Chapter 16Table 16.1 Results of viability test for HeLa cell line after treatment by AgNPs...Table 16.2 Bactericidal activity of silver nanoparticles synthesized by Mangifer...Table 16.3 Fungicidal activity of silver nanoparticles synthesized by Mangifera ...

12 Chapter 18Table 18.1 NPs associated nanovaccines and their applications.Table 18.2 Natural andsynthetic sources of nanovaccines.

13 Chapter 19Table 19.1 Commercially available oral vaccines with details.